Kyorin Licenses Merck’s OAB Drug Vibegron For Japan
Kyorin Pharmaceuticals has entered into a licensing agreement with U.S.-based Merck & Co for the overactive bladder drug vibegron, hoping to expand its product lineup in the urology field.
Kyorin Pharmaceuticals has entered into a licensing agreement with U.S.-based Merck & Co for the overactive bladder drug vibegron, hoping to expand its product lineup in the urology field.